Eden Biodesign and the University of Manchester Intellectual Property Limited develop cancer treatment
Professor Paul Bishop, School of Medicine, University of Manchester, who leads the team that discovered the new therapeutic, commented: "We are very pleased for this exiting programme to be further developed by Eden Biodesign. The experience of Eden Biodesign's management team in the development of biologics ensures that our programme will be well positioned for an accelerated clinical development and will increase the value of our programme to industrial partners."
Professor Paul Bishop has been awarded a grant from the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA) towards the cost of the project. The project will be executed at the state of the art NBC, operated by Eden Biodesign and funded by NWDA, European Regional Development Fund (ERDF) and Department of Trade and Industry (DTI). "We are pleased that the NBC is able to provide practical help to Professor Paul Bishop and UMIP Ltd for the commercialisation of their discoveries which have the potential to offer both patient benefit and consolidation of the UK's lead in biopharmaceutical development in Europe" said Dr Linda Magee, NWDA Biotechnology Sector Director & Head of Bionow.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.